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Objectives.Humanplacentalextract(HPE)hasbeguntobeusedinKoreainvariouswaystoimprovehealth,eventhoughevidence-
based data is insuﬃcient. This study investigated the eﬀects of HPE on health status in elderly Koreans. Design.R a n d o m i z e d ,
single-blind, and case-control study design. Setting and Participants. Thirty-nine community-dwelling healthy Koreans ≥65 years
of age. Intervention. The participants were randomly categorized into a placebo group (n = 17) and HPE group (n = 22). The
HPE group received abdominal subcutaneous injections of HPE for 8 weeks. The placebo group was injected with normal saline.
Measurements. The degree of health status was surveyed by the Korean health status measure for the elderly (KoHSME V1.0)
at baseline and the end of the study. Results. In the HPE group, the scores of physical function, sexual life, and general heath
perception at the end of the study period were signiﬁcantly improved from baseline (P = .007, .020, and .005, resp.), while the
health status of the placebo group remained unchanged during the study period. There was a signiﬁcant diﬀerence over the study
period between the two groups in the mean change of the physical function score (P = .036). Conclusion. A HPE injection regimen
can improve the health status in elderly Koreans.
1.Introduction
H umanplacentahasbeenahistoricalfolkremedyinOriental
countries. In Japan, the hydrolysate of human placenta,
which contains therapeutic compounds, has long been
reﬁned as human placental extract (HPE). In Korea, HPE
has been approved for the improvement of liver function
and menopausal symptoms since its importation from Japan
in 2003. In Korea, HPE has been approved and is now
widely used for improvement of fatigue, skin whitening, and
antiaging.Despitethispopularity,theeﬃcacyofHPEhasnot
been suﬃciently researched.
Studies using animal models have provided evidence for
liver function improvement and skin whitening attributes of
HPE by liver regeneration and antimelanocyte activity [1–
5].Improvementsofmenopausalsymptomsandfatiguehave
been indicated in several studies, including one from our
group [6, 7].
With the aim of investigating HPE in more rigor-
ous detail, the present randomized controlled trial was
undertaken to determine the inﬂuence of HPE on the health
status in elderly Koreans.
2. Methods
2.1. Study Approval. This study was approved by the Insti-
tutional Review Board of Ajou University Hospital, Suwon,
Republic of Korea (AJIRB-CRO-05-211).
2.2. Participants. A public notice posted on the notice
board of Ajou University Hospital between May and July,
2006, recruited research participants. Details of the study
were explained to potential volunteers prior to obtaining
informed consent.
Initial screening included past/current medical history
and a physical examination. Eligible participants were Kore-
ans ≥65 years of age. Subjects with history of chronic
renal disease were excluded if their plasma creatinine levels
exceeded 1.5mg/dL, if they had history of liver cirrhosis or2 Evidence-Based Complementary and Alternative Medicine
otherhemmorhogicdiseases,historyofanycancer,orhistory
oftakingmedicationssuchasthrombolyticagents.Forty-two
subjects(20males,22females)wereselected.Thesamplesize
calculationswerebasedontheassumptionsofastandardized
eﬀect size of 0.90, statistical power of 95%, and a (1-sided)
type I error 5%. To meet these assumptions, 42 patients were
required.
2.3. HPE Preparation and Study Design. The hydrolysate
of human placenta (HPE; Laennec; Green Cross Japan Bio
Products, Yongin, Korea) has been previously described [6].
It is an aqueous extract of human placenta that is approved
by the Korea Food and Drug Administration for sale and
use in the treatment of chronic liver diseases. To prepare
the product, human placenta collected at the time of full-
term delivery was immediately placed in ice. Each placenta
is tested to ensure the absence of human immunodeﬁciency
virus, hepatitis B virus, and hepatitis C virus. The acceptable
placentas are cut into pieces and extracted with water
through enzymatic molecular separation and chemical
hydrolysis. Hydrolysis utilizes hydrochloric acid and heating
for 15–17 hours. At the ﬁnal process, the extract is sterilized
by steam at 121◦C for 30 minutes and sealed in ampoules for
sale.
The subjects were randomly assigned to receive
subcutaneous injection of either placebo (normal saline,
n = 18) or HPE (n = 22) for 8 weeks. Participants were
injected with the appropriate preparation in the following
schedule: 4mL twice weekly for the ﬁrst 2 weeks, 2mL twice
aweekforthenext2weeks,and2mLonceweeklyforthelast
4weeks.Eachparticipantvisitedthehospital12timesduring
the 8-week study for the injection, and the total amount
injected was 32mL. All subjects had their eyes covered
during injection to blind them to the identity of the injected
preparation. Health status was assessed by a questionnaire
and metabolic parameters including cardiovascular risk
factors that were measured at baseline and after 8 weeks.
2.4. Questionnaire for Assessment of Health Status. The sur-
vey questionnaire for Korean Health Status Measure for the
Elderly (KoHSME V1.0) [8] was used. KoHSME consists
of a list of 44 items, which each has a 1–5 Likert response
scale, except for pain intensity, which uses a visual analogue
scale. The composite score is the sum of six dimension
scores: physical function (19 items), emotional function (13
items), social function (6 items), sexual function (1 item),
general health perception (3 items), and bodily pain (2
items). Four dimension scores (physical function, emotional
function, general health perception, and bodily pain) have
subscales. The physical function score includes daily activity,
ﬁtness, and aging physiological function subscales. The
emotional function score includes depression and anxiety
subscales. The general health perception score includes
healthstatusperception,healthstatuschange,andfunctional
health satisfaction subscales. The bodily pain includes pain
frequency and intensity subscales. The internal correlation
reliability of physical function was 0.94, emotional function
was 0.90, and social function was 0.90 at the time of
development of this questionnaire.
2.5. Metabolic Parameters. Body measurement and meta-
bolic parameters were similar to those of our prior study
[6], including body mass index (BMI), blood pressure,
hemoglobin, platelet count, white blood cell count, glu-
cose, aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), and gamma glutamyl transpeptidase (γ-GTP).
Metabolic parameters were measured exactly as described
previously [6]. Insulin-like growth factor 1 (IGF-1) was
also measured using an IRMA kit (Diagnostic Systems
Laboratories, Webster, TX, USA).
2.6. Statistical Analyses. Statistical analyses utilized SPSS
for windows, version 11.5 (SPSS, Chicago, IL, USA). A
nonparametric test was used to compare HPE with placebo
at baseline and the end of the study (continuous variables
by Mann-Whitney test, categorical variables by Pearson Chi-
square or Fisher’s Exact test). Wilcoxon-signed rank test was
used to assess the change in each group at the beginning and
end of the study period. All values are shown as mean ±
standard deviation (SD). A P value <0.05 indicated statistical
signiﬁcance.
3. Results
One subject in the placebo group did not complete the study,
withdrawing for a personal reason. Thirty-nine participants
completed the study (22 in the HPE group and 17 in the
placebo group).
3.1. Clinical Characteristics. There were no signiﬁcant
diﬀerences between the HPE and placebo groups at base-
line concerning gender, age, BMI, prevalence/nature of
cardiovascular diseases, use of antihypertensive medication,
use of oral hypoglycemic agents for diabetes, and use of
medication for hyperlipidemia (Table 1). Laboratory test
results (Table 1) were also similar between the two groups.
3.2. Changes in Health Status. All mean KoHSME scores did
not diﬀer signiﬁcantly between the HPE and placebo groups
at baseline. In the HPE group, the mean scores of physical
function, sexual function, and general health perception at
the end of the study period were signiﬁcantly improved from
those at baseline (Table 2). Although the mean scores of
emotional function and bodily pain were not diﬀerent at
baselineandtheendofthestudyperiod,thedepressionscore
with subscale of the emotional function and pain frequency
score with subscale of the pain at the end of the study period
were signiﬁcantly improved, compared to baseline (Table 2).
However, all health status scores in the placebo group were
notsigniﬁcantlydiﬀerentatbaselineandtheendofthestudy.
There was a signiﬁcant diﬀerence between the two groups
in the mean change of physical function score during the
study period (P = 0.036, Table 2). In particular, the aging
physiological function score with subscale of the physical
function diﬀered signiﬁcantly through the study (P<0.001,
Table 2).
3.3. Changes of Risk Factors of Cardiovascular Disease.
There were no signiﬁcant changes in the risk factors ofEvidence-Based Complementary and Alternative Medicine 3
Table 1: Comparison of clinical and biochemical characteristics between the two study groups at baseline.
Placebo (n = 17) HPE (n = 22) P value
Male patient, no. (%) 9 (52.9) 10 (45.5) 0.643
DM, no. (%) 2 (11.8) 4 (18.2) 0.679∗
HTN, no. (%) 7 (41.2) 14 (63.6) 0.163
Hyperlipidemia, no. (%) 3 (17.6) 3 (13.6) 1.000∗
Age (years) 69.1 ±3.56 8 .0 ±2.4 0.353
Weight (kg) 65.6 ±7.36 5 .9 ±10.6a 0.907
BMI (kg/m2)2 5 .2 ±2.62 5 .8 ±3.4a 0.780
Hemoglobin (g/dL) 13.9 ±1.11 4 .3 ±1.1 0.444
Platelets (×103/μL) 236.2 ±51.6 247.4 ±79.3 0.734
WBC (×103/μL) 7.139 ±1.776 6.505 ±1.449 0.436
Creatinine (mg/dL) 0.9 ±0.20 .9 ±0.2 0.697
AST (U/L) 20.6 ±5.22 2 .2 ±10.7 0.921
ALT (U/L) 20.1 ±7.62 3 .1 ±16.1 0.798
γ-GTP (U/L) 19.7 ±9.32 2 .5 ±7.8 0.152
IGF-1 (μIU/mL) 180.4 ±82.0 197.6 ±86.3 0.444
Mean ± SD, aone data point missing, HPE: human placental extract, DM: diabetes, HTN: hypertension, BMI: body mass index, WBC: white blood cell count,
AST: asparate aminotransferase, ALT: alanine aminotransferase, γ-GTP: gamma glutamyl transpeptidase, IGF-1: Insulin-like growth factor-1, and P: group
diﬀerence of continuous variable using Mann-Whitney test and categorical variable by Pearson Chi-square test, ∗b yF i s h e r ’ sE x a c tt e s t( d / tc e l l sh a v ee x p e c t e d
count <5).
Table 2: Change of KoHSME in the two study groups.
Placebo (n = 17) HPE (n = 22)
P ‡ value (Placebo versus HPE)‡
Baseline End P† Baseline End P†
Physical function 3.6 ±0.7c 3.5 ± 0.7b 0.625 3.5 ±0.5a 3.8 ± 0.5a 0.007 0.036
Daily activity 4.1 ±0.6c 3.9 ± 0.7b 0.420 4.2 ±0.5a 4.1 ± 0.7a 0.983 0.657
Fitness 3.5 ±0.9b 3.6 ± 0.7a 0.316 3.4 ±0.73 .6 ±0.6 0.111 0.493
Aging physiological function 3.2 ± 0.8a 3.0 ± 0.8a 0.116 3.0 ±0.63 .7 ±0.5 0.001 <0.001
Emotional function 3.7 ±0.6a 3.7 ± 0.6b 0.690 3.6 ±0.73 .8 ±0.6a 0.067 0.440
Depression 3.9 ±0.7a 3.9 ± 0.7b 0.569 3.6 ±0.83 .9 ±0.7a 0.025 0.479
Anxiety 3.4 ± 0.7a 3.3 ±0.6b 0.727 3.5 ±0.63 .7 ±0.7 0.364 0.493
Social function 3.6 ± 1.2a 3.7 ±0.8a 0.699 3.7 ±0.73 .7 ±0.7 0.881 0.858
Sexual function 2.5 ±1.2a 3.0 ±1.3b 0.230 2.4 ±1.13 .0 ±1.1a 0.020 0.620
General health perception 2.7 ±0.6a 2.5 ± 0.5a 0.254 2.9 ±0.52 . 6 ± 0.6a 0.005 0.618
Health status perception 2.8 ±0.9a 2.6 ±0.9a 0.470 2.8 ±0.72 .9 ±0.7 0.763 0.477
Health status change 2.8 ±0.6a 2.4 ±0.7a 0.083 3.0 ±0.62 .3 ±0.6 0.002 0.218
Functional health satisfaction 2.6 ±0.9a 2.5 ±1.1a 0.717 3.0 ±0.72 .5 ±0.9a 0.004 0.338
Bodily pain 2.7 ±0.9a 3.4 ±0.9b 0.149 2.9 ±0.93 .4 ±0.8b 0.053 0.892
Pain frequency 2.4 ±1.3a 3.2 ±1.2a 0.067 2.6 ±1.23 .3 ±0.6 0.043 0.843
Pain intensity 53.4±21.5a 61.7±18.5b 0.560 58.2±19.25 9 .5±20.9b 0.569 0.812
Mean ±SD, a1datamissing,b2datamissing, c:3datamissing, †changebetweenendandbaselineineachgroup(byWilcoxonsignedrankstest), ‡comparison
of mean change between HPE and placebo groups (by Mann-Whitney test), KoHSME; Korean Health Status Measure for the Elderly, and HPE: human
placental extract.
cardiovascular disease in the two groups during the study
period, including blood pressure, fasting plasma glucose,
insulin, insulin resistance index (HOMA-IR, QUICKI), lipid
levels(totalcholesterol,triglyceride,high-densitylipoprotein
cholesterol), and high sensitivity C-reactive protein level
(Table 3).
4. Discussion
The proportion of the elderly in Korean society and globally
is increasing rapidly as advances in medical science permit a
longer life. With an extended life span, the quality of life and
health status of the elderly, especially concerning depression4 Evidence-Based Complementary and Alternative Medicine
Table 3: Change of risk factors of cardiovascular disease in the two study groups.
Placebo HPE P value (Placebo
versus HPE)‡ Baseline
(n = 18) End (n = 17) Diﬀerence† Baseline
(n = 22)
End
(N = 22) Diﬀerence†
SBP (mmHg) 132.1 ± 11.9a 129.6 ± 15.1c −0.8 ± 16.4c 132.8 ± 11.24d 135.5 ± 13.0b 2.5 ± 11.3bd 0.860
DBP (mmHg) 81.5 ± 6.1a 85.0 ± 8.3c 4.6 ± 10.5c 83.9 ± 8.9 83.7 ± 9.0b 0.5 ± 9.6b 0.250
FPG (mg/dL) 101.8 ±11.5 100.1 ± 9.7d −1.9 ± 6.8d 102.5 ± 13.32e 97.0 ± 11.6f −1.0 ± 9.3f 0.842
Insulin (μIU/mL) 6.4 ±3.75 .0 ±3.7 −1.5 ±3.87 . 9 ± 3.8d 7.3 ± 5.0d −1.2 ±4.3 0.640
HOMA-IR 1.62 ±1.02 1.13 ±0.77 −0.51 ±0.93 1.95 ± 1.06d 1.90 ± 1.42d −0.05 ± 0.85d 0.094
QUICKI 0.37 ±0.04 0.40 ±0.06 0.03 ±0.04 0.35 ±0.05 0.36 ±0.05 0.01 ±0.03 0.062
Total cholesterol (mg/dL) 186.0 ±34.0 184.8 ±35.0 −2.1 ±22.5 197.7 ± 36.9 195.4 ±46.7 −2.3 ±25.0 0.843
Triglyceride (mg/dL) 149.9 ±64.3 144.6 ±47.8 −8.4 ±55.1 167.1 ± 83.3 143.3 ± 57.9d −5.0 ±61.2 0.966
HDL cholesterol (mg/dL) 51.8 ±10.55 0 .8 ±5.9 −0.8 ±7.44 9 .9 ± 9.05 0 .2 ±7.51 . 7 ± 7.1d 0.480
hs-CRP (mg/dL) 0.12 ± 0.11d 0.08 ± 0.05e −0.36 ± 1.35e 0.15 ± 0.15d 0.17 ± 0.19d 0.002±0.105 g 0.731
Mean ± SD, a1 data missing, b3d a t am i s s i n g ,c5d a t am i s s i n g ,d1 data exclusion d/t extreme value within group, e2 data exclusion d/t extreme values within
group, f3 data exclusion d/t extreme values within group, g4 data exclusion d/t extreme values within group, †change from baseline (after-baseline), ‡Pv a l u e s
are for the comparison between groups (change from baseline), HPE: human placental extract, SBP: systolic blood pressure, DBP: diastolic blood pressure,
FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment of insulin resistance, QUICKI: the quantitative insulin sensitivity check index, HDL:
high-density lipoprotein, and hs-CRP: high-sensitivity C reactive protein.
and physical function, have become very important issues.
Depression in elderly people is an important cause of weight
loss, cognitive dysfunction, and death [9–11].
In the present study, health status improved in elderly
Koreans (≥65-years-of-age) when they received an 8-week
regimen of HPE injections. Improvements noted in general
physical function in accord with the improved physiologic
function and depressive mood were improved at the end of
the study period, while these aspects were unchanged in the
placebogroup.Aginghasbeenlinkedtoincreasedinﬂamma-
tion [12]. The demonstrated anti-inﬂammatory activity of
HPE [13, 14] suggests that HPE has potential in modulating
age-related inﬂammation, with consequent health beneﬁts.
Furthermore,HPEisarichresourceofvariousbioactivesub-
stances such as RNA, DNA, peptides, aminoacids, proteins,
lipids, and enzymes [15, 16]. The anabolic eﬀect of these
components assists energy production, which may improve
age-related physical functions. Improved physical function
could lessen the development of depression in the elderly.
The present study also assessed the inﬂuence of HPE on
sexual functioning. Although IGF-1 was not changed, the
noted improvement in sexual function may have reﬂected
the general physiologic function improvement mediated
by HPE. HPE displays anti-inﬂammatory activity that is
the same as diclofenac [13] .T h el e s s e n e dp a i nf r e q u e n c y
noted in participants receiving HPE can be explained by the
anti-inﬂammatory eﬀect of HPE. Lessened pain would be
anticipated to lessen a depressive mood.
The current study is limited by the small number of
participants, the use of only Koreans, and the lack of a
long-term assessment. Further studies must address these
shortcomings before the signiﬁcance of the present ﬁndings
can be veriﬁed. Also, the eﬀectiveness of HPE treatment
needs to be explored further in a global approach, in terms
of diﬀerent cultures and habits. Despite the limitations, the
study is notable for the demonstration of improved health
status in elderly Koreans who received HPE for 8 weeks.
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